检验医学与临床
檢驗醫學與臨床
검험의학여림상
Laboratory Medicine and Clinic
2015年
22期
3318-3320,3322
,共4页
浸润性乳腺癌%紫杉醇%蒽环类%人类表皮生长因子受体-2
浸潤性乳腺癌%紫杉醇%蒽環類%人類錶皮生長因子受體-2
침윤성유선암%자삼순%은배류%인류표피생장인자수체-2
invasive breast cancer%paclitaxel%anthracyclines%HER-2
目的:分析紫杉醇及蒽环类药物联合化疗对浸润性乳腺癌人类表皮生长因子受体‐2(H ER‐2)状态的影响。方法选择2013年4月至2014年5月收治的98例浸润性乳腺癌患者,按照入院顺序将患者分为观察组(49例)和对照组(49例)。对照组采取CAF方案进行治疗,观察组患者采取CTX方案+紫杉醇及蒽环类药物。对所有患者的化疗方案和临床病理特征进行记录,主要为腋窝淋巴结状态、激素受体状态以及 H ER‐2表达状态。结果在 H ER‐2阳性的患者当中,观察组患者的无病生存率为95.00%(38/40),对照组患者的无病生存率为65.79%(25/38),两组比较差异有统计学意义( P<0.05);就激素受体阳性的患者而言,观察组患者的无病生存率是91.43%(32/35),明显高于对照组的72.22%(26/36),差异有统计学意义( P<0.05);在腋窝淋巴结阳性的患者中,观察组患者的无病生存率是95.24%(40/42),明显高于对照组的71.79%(28/39),差异有统计学意义( P<0.05)。结论紫杉醇及蒽环类药物联合化疗能够改善浸润性乳腺癌HER‐2阳性状态。
目的:分析紫杉醇及蒽環類藥物聯閤化療對浸潤性乳腺癌人類錶皮生長因子受體‐2(H ER‐2)狀態的影響。方法選擇2013年4月至2014年5月收治的98例浸潤性乳腺癌患者,按照入院順序將患者分為觀察組(49例)和對照組(49例)。對照組採取CAF方案進行治療,觀察組患者採取CTX方案+紫杉醇及蒽環類藥物。對所有患者的化療方案和臨床病理特徵進行記錄,主要為腋窩淋巴結狀態、激素受體狀態以及 H ER‐2錶達狀態。結果在 H ER‐2暘性的患者噹中,觀察組患者的無病生存率為95.00%(38/40),對照組患者的無病生存率為65.79%(25/38),兩組比較差異有統計學意義( P<0.05);就激素受體暘性的患者而言,觀察組患者的無病生存率是91.43%(32/35),明顯高于對照組的72.22%(26/36),差異有統計學意義( P<0.05);在腋窩淋巴結暘性的患者中,觀察組患者的無病生存率是95.24%(40/42),明顯高于對照組的71.79%(28/39),差異有統計學意義( P<0.05)。結論紫杉醇及蒽環類藥物聯閤化療能夠改善浸潤性乳腺癌HER‐2暘性狀態。
목적:분석자삼순급은배류약물연합화료대침윤성유선암인류표피생장인자수체‐2(H ER‐2)상태적영향。방법선택2013년4월지2014년5월수치적98례침윤성유선암환자,안조입원순서장환자분위관찰조(49례)화대조조(49례)。대조조채취CAF방안진행치료,관찰조환자채취CTX방안+자삼순급은배류약물。대소유환자적화료방안화림상병리특정진행기록,주요위액와림파결상태、격소수체상태이급 H ER‐2표체상태。결과재 H ER‐2양성적환자당중,관찰조환자적무병생존솔위95.00%(38/40),대조조환자적무병생존솔위65.79%(25/38),량조비교차이유통계학의의( P<0.05);취격소수체양성적환자이언,관찰조환자적무병생존솔시91.43%(32/35),명현고우대조조적72.22%(26/36),차이유통계학의의( P<0.05);재액와림파결양성적환자중,관찰조환자적무병생존솔시95.24%(40/42),명현고우대조조적71.79%(28/39),차이유통계학의의( P<0.05)。결론자삼순급은배류약물연합화료능구개선침윤성유선암HER‐2양성상태。
Objective To analyze the impact of the combined chemotherapy of paclitaxel and anthracycline drugs on human epidermal growth factor receptor 2(HER‐2) status in invasive breast cancer .Methods 98 cases of invasive breast cancer in our hospital from April 2013 to May 2014 were selected and divided into the observation group(49 cases) and the control group(49 cases) according to the admission order .The control group took the CAF scheme for conducting treatment ,while the observation group adopted the CTX scheme plus paclitaxel and anthracy‐clines drugs .The chemotherapeutic schemes and clinicopathological features were recorded ,mainly including axillary lymph node status ,hormone receptor status and HER‐2 expression status .Results In the patients with HER‐2‐posi‐tive ,the disease‐free survival rate in the observation group was 95 .00% (38/40) ,which in the control group was 65 .79% (25/38) ,the difference was statistically significant(P<0 .05);in the hormone receptor‐positive patients ,the disease‐free survival rate in the observation group was 91 .43% (32/35) ,which was significantly higher than 72 .22%(26/36) in the control group ,the difference was statistically significant(P<0 .05);in the axillary lymph node‐posi‐tive patients ,the disease‐free survival rate in the observation group was 95 .24% (40/42) ,which was significantly higher than 71 .79% (28/39) in the control group ,the difference was statistically significant(P<0 .05) .Conclusion The combination chemotherapy of paclitaxel and anthracycline drugs can improve the HER‐2‐positive status in inva‐sive breast cancer .